Are you Dr. Smyth?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
300 E 66th St
New York, NY 10065Phone+1 212-639-2000Fax+1 212-639-2283
Summary
- Dr. Lillian Smyth, MD is an oncologist in New York, New York. She is currently licensed to practice medicine in New York. She is affiliated with Memorial Sloan Kettering Cancer Center.
Education & Training
University College of Dublin National Univ SOMClass of 2006
Certifications & Licensure
NY State Medical License 2014 - 2019
Clinical Trials
- AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations Start of enrollment: 2017 Oct 11
Publications & Presentations
PubMed
- 1 citationsNatural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AA...Michele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, David M Hyman, Natalie Blauvelt
Clinical Cancer Research. 2022-05-13 - 10 citationsAKT mutant allele-specific activation dictates pharmacologic sensitivities.Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N Gorelick, Matthew T Chang, Debyani Chakravarty
Nature Communications. 2022-04-19 - 68 citationsEnhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.A. Rose Brannon, Gowtham Jayakumaran, Monica Diosdado, Juber Patel, Anna Razumova
Nature Communications. 2021-06-18
Authored Content
- Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined Through AACR Project GENIE, a Clinicogenomic RegistryMarch 2020
Press Mentions
Press Release: Knight Therapeutics Acquires Exclusive Marketing Rights to Nerlynx in CanadaJanuary 11th, 2019
